Aids in diagnosis of urothelial carcinoma in conjunction with standard diagnostic procedures and monitoring for tumor recurrence.
Quantitative Enzyme Immunoassay
NMP22 testing should not be performed on patients who have had a total cystectomy or within 5 days of an invasive procedure, such as cystoscopy or catheterization of the urethra.
Single void of urine collected between midnight and noon. Urine Stabilization kit required (ARUP Supply #12594). Available online through eSupply using ARUP Connect™ or by contacting ARUP Client Services at (800) 522-2787.
Follow instructions provided in the Urine Stabilization kit. Stabilized specimen should be blue/green in color.
Urine not stabilized in NMP22 Urine Stabilizer Vial.
Preserved: Ambient: 4 days; Refrigerated: 7 days; Frozen: 2 months
This test is intended as an aid in the management of patients with transitional cell carcinoma of the urinary tract (TCC/UT), and is used after surgical treatment to identify patients with residual or rapidly recurring TCC/UT. Values obtained with different test methods should not be used interchangeably. ARUP uses the Alere NMP22 Test Kit, an enzyme immunoassay (EIA) method. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
|Component Test Code*||Component Chart Name||LOINC|
- Bladder Tumor Associated Antigen
- Nuclear Matrix Protein